Pharmadrug Inc.
Pharmadrug Inc. (PHRX.CN) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Pharmadrug Inc. (PHRX.CN), featuring income statements, balance sheets, and cash flow data.
Pharmadrug Inc. (PHRX.CN) Income Statement & Financial Overview
View the income breakdown for Pharmadrug Inc. PHRX.CN across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $12561.00 | $12561.00 | $12561.00 | $12561.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | -$12561.00 |
| Gross Profit Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| R&D Expenses | $0.00 | $97646.00 | $6422.00 | -$31208.00 |
| SG&A Expenses | $33875.00 | -$9919.00 | $29120.00 | $19469.00 |
| Operating Expenses | $36995.00 | $87727.00 | $43927.00 | $15192.00 |
| Total Costs & Expenses | $49556.00 | $100288.00 | $56488.00 | $52177.00 |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $52934.00 | $0.00 | $112532.00 | $82155.00 |
| Depreciation & Amortization | $12561.00 | $12561.00 | $12561.00 | $12561.00 |
| EBITDA | -$51582.00 | -$7753.00 | -$55866.00 | -$49301.00 |
| EBITDA Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | -$49556.00 | -$100288.00 | -$56488.00 | -$52177.00 |
| Operating Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Other Income/Expenses (Net) | -$67521.00 | $93255.00 | -$124471.00 | -$91840.00 |
| Income Before Tax | -$117077.00 | -$7033.00 | -$180959.00 | -$144017.00 |
| Income Before Tax Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$100111.00 | $6084.00 | -$171277.00 | -$144017.00 |
| Net Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS | -$0.001 | $0.00 | -$0.002 | -$0.001 |
| Diluted EPS | -$0.001 | $0.00 | -$0.002 | -$0.001 |
| Weighted Avg Shares Outstanding | $107.77M | $105.85M | $104.14M | $100.39M |
| Weighted Avg Shares Outstanding (Diluted) | $107.77M | $105.85M | $104.14M | $100.39M |
The company's financials show resilient growth, with revenue advancing from $0.00 in Q2 2024 to $0.00 in Q1 2025. Gross profit remained healthy with margins at N/A in Q1 2025 compared to N/A in Q2 2024. Operating income hit -$49556.00 last quarter, sustaining a consistent N/A margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$51582.00. Net income dropped to -$100111.00, while earnings per share reached -$0.001. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan